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S170 Oral PresentationsConclusion: These demonstrated that safety and feasibility of third
party UCB-derived MSCs use and co-infusion of UCB-derived
MSCs can overcome graft dysfunction of UCBT.HISTOCOMPATIBILITY/ALTERNATIVE STEM
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CORD BLOOD (CB) APGAR SCORE IS PREDICTIVE OF NEUTROPHIL
ENGRAFTMENT AND GRAFT FAILURE PROBABILITIES FOR PLASMA
DEPLETED/REDUCED CB PRODUCTS
Chow, R.1,2, Wang, B.C.1, Chou, D.1, Chow, M.1, Wu, T.1, Kang, J.2,
Petz, L.D.1, Kurtzberg, J.3 1StemCyte International Cord Blood Center,
Covina, CA; 2StemCyte Taiwan National Cord Blood Center, Linkou,
Taiwan; 3Duke University Medical Center, Durham, NC
Nucleated cell (NC), CD341 cell (CD34), and colony forming unit
(CFU) doses have been proposed to measure CB potency - important
for engraftment potential prediction and transplantation product selec-
tion.ThoughTNCiswidelyused forCBselection, its predictive value is
not as robust as the progenitor cell measurements. CFU andCD34 suf-
fer from high inter-laboratory coefficient of variance (CV) - decreasing
the clinical utility as potency measures. Recently, the Duke Group pro-
posed a CB APGAR scoring system composed of (a) a Pre-Cryopre-
served Score (PCS) reflecting pre-freeze CFU, CD34, NC, and CB
collected volume, aswell as a (b)Composite Score (CS)which combines
the PCS score with post-thaw NC, CD34, CFU and mononuclear cell
dose. Based on single, myeloablative and first (SMF) transplants of
largely pediatric patients performed at Duke and using mostly red cell
reduced (RCR)CB, the PCS andCS scores were shown to be predictive
of graft failure, neutrophil and platelet engraftment. With CIBMTR-
auditedoutcomedataof transplantedCBproducts fromamulti-national
CBbank,we sought to validate theCBAPGARsystemonapatient pop-
ulationwithmostly adults, heavy representationofminority and interna-
tional patients, and on both SMF transplants, and all transplants (All)
using plasma depleted/reduced (PDR) CB products. The PCS and CS
table below shows the day 42 neutrophil engraftment cumulative inci-
dence (ANC500) and graft failure probability (GF) comparisons of the
Duke data with PDR transplants for both SMF and All transplants.
For each of the PCS and CS strata compared, ANC500 and GF ap-
peared to be similar among theDuke SMF, StemCyte SMF and All co-
horts.We conclude that theCBAPGARscore, especially the PCS, is an
easy-to-use and reproducible potencymeasurement forCB selection by
transplant centers that is highly predictive of ANC500 engraftment and
GF for (1) RCRaswell as PDRCB, (2) formostly pediatric patient pop-
ulationaswell as formixedpopulationsof adults andchildren, and (3) for
minority and international patients.Whether themethod canbe applied
to double, non-myeloablative and repeat CB transplants remains to be
seen.Lastly, for the samePCSorCSstrata,PDRCBappear tohave sim-
ilar engraftment and GF probabilities as RCRCB; therefore, the Duke
CB APGAR is applicable to CB products with or without RBC reduc-
tion and reflects potencyofCBproducts processed and storedby various
methods at different CB banks.
Table 1. ANC 500 Engraftment Cumulative Incidence & Graft
Failure Probabilities
ANC 500 Duke SMF PDR SMF PDR AllPCS$7.75 93% (86-100%) 100±18% 83±19%
PCS<7.75 75% (69-81%) 78±9% 76±4%
HR 2.44 (1.78 - 3.59) 2.43 (0.85 - 6.95) 1.92 (0.78 - 4.68)
CS$13.5 90% (84 - 95%) 94±14% 84±11%
CS<13.5 69% (61 - 78%) 68±12% 77±6%
HR 2.31 (1.73 - 3.08) 1.54 (0.73 - 3.26) 1.19 (0.78 - 1.82)Graft Failure
ProbabilityDuke SMF PDR SMF PDR AllPCS$7.75 7% (3-17%) 0±18% 17±19%
PCS$5.5 & <7.75 19% (12-30%) 15±14% 18±10%
PCS$4.25 & <5.5 26% (16-39%) 6±13% 14±9%
PCS<4.25 32% (22-45%) 38±12% 29±5%50
IN-VIVO EXPANSION OF T REGULATORY CELLS BY RAPAMYCIN IN A
CALCINEURIN-INHIBITOR FREE GVHD PROPHYLAXIS IN UNMANIPU-
LATED HAPLOIDENTICAL STEM CELL TRANSPLANTATION (SCT)
Peccatori, J.1, Clerici, D.1, Forcina, A.1, Bondanza, A.2, Messina, C.1,
Giglio, F.1, Mastaglio, S.1, Crotta, A.1, Lupo Stanghellini, M.T.1,
Marcatti, M.1, Crocchiolo, R.1, Assanelli, A.1, Bernardi, M.1, Corti, C.1,
Noviello, M.2, Olek, S.3, Ferraro, A.4, Battagglia, M.4, Roncarolo, M.G.5,
Locatelli, F.6, Bonini, C.2, Ciceri, F.1 1San Raffaele Scientific Institute, Mi-
lan, Italy; 2San Raffaele Scientific Institute, Milan, Italy; 3Epiontis Gmb,
Berlin, Germany; 4San Raffaele Scientific Institute,Milan, Italy; 5San Raf-
faele Scientific Institute,Milan, Italy; 6 IRCCSOspedale Pediatrico Bambino
Gesu, Roma, Italy
Background:Tregs are attractive candidates for clinical modulation
of excessive immune responses. In SCT mouse models, the adoptive
transfer of purified natural Tregs has been shown to prevent GvHD,
while sparing a significant GvL effect. Tregs’ suppressor function
has been demonstrated to be critically dependent on IL-2, therefore
cyA significantly reduces the function of allostimulated Tregs.
Aim: To address the role of Tregs in human SCT, we focused on
a calcineurin inhibitor-free GvHD prophylaxis. We tested this hy-
pothesis in haploidentical peripheral blood stem cells SCT without
any in-vitro manipulation.
Patients and Methods: Since 2007, 68 pts underwent allo-SCT for
AML (43), ALL (9),MDS (3),MPD (4), NHL (4) orHD (5).Median
age was 48 years (range 14-69). At SCT all but 8 pts were in advanced
phase. Conditioning included Treosulfan (14 g/m2 for 3), Fludara
(30 mg/m2 for 5) and an in-vivo T and B-cell depletion, by ATG-
Fresenius (10 mg/kg for 3) and Mabthera (a single 500 mg dose).
All pts received allogeneic PBSC from an HLA-haploidentical
related donor without any in-vitro positive selection. GvHDprophy-
laxis consisted of Rapamycin (target level 8-15 ng/ml, till day 160)
and MMF (15 mg/kg tid till day 130).
Results: All pts but 3 had neutrophil engraftment. CI of grade 2-4,
grade 3-4 aGvHD and cGvHD were 22%, 11% and 26%. 100 days
TRM and relapse incidence at 1 year were 17% and 44%. Projected
OS at 1 year is 39%. Immunoreconstitution was fast and sustained
with amedian 220 circulatingCD31cells/mLonday130.Wedetected
high levels of CD41CD251CD127- FOXP31 Tregs (up to 30% of
circulating CD41 T lymphocytes) on day 130. These cells were able
to suppress in vitroproliferationof autologous effector cells.Thisobser-
vation was further reinforced at a molecular level.We applied a quanti-
tative RT-PCR based methylation assay that enables a specific and
sensitive determination of T regs numbers by measuring demethylated
FOXP3atT reg specific demethyleted region (TSDR).Anexpansionof
cells carrying FOXP3 demethylation was evident in our pts, but not in
a control group of pts receiving mismatched SCT and cyclosporine.
Conclusions: Rapamycin-Mycophenolate-ATG are effective as
GvHD prophylaxis in unmanipulated haploidentical peripheral SCT
andare associatedwith an earlyT-cell immunoreconstitution character-
ized by the in-vivo expansion of Tregs. Further studies are warranted to
gain insight correlations between Tregs expansion and SCT outcome.
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8/8 HIGH-RESOLUTION HLA MATCH RATE: THE IMPACT OF RACE
Dehn, J.1, Buck, K.1, Yang, S.Y.2, Schmidt, A.3, Hartzman, R.4,
Maiers, M.1, Setterholm, M.1, Confer, D.1 1National Marrow Donor
Program, Minneapolis, MN; 2Histogenetics, Inc., Ossining, NY;
3DKMS, Tuebingen, Germany; 4C.W. Bill Young Marrow Donor Re-
cruitment and Research Program, Rockville, MD
Aim: Calculation of the 8/8 (HLA-A, B, C, DRB1) high-resolution
(HR) match rate using real patient unrelated donor (URD) searches
presents a biased sample for reasons including access to treatment, fi-
nancial barriers and incomplete donor testing. A study was designed
to estimate the truematch rate forCaucasian (CAU),Hispanic (HIS),
Asian/Pacific Islander (API), and African American (AFA) groups,
representing the four largest race groups in the US population.
Methods: 1344 URD searches were performed for pseudopatients
(PP) who were randomly selected, previously HR tested donors in
the NMDP’s Be The Match Registry (BTMR). Searches were based
on a fixed BTMR file as of January 2009. Search results from CAU,
HIS, API, and AFA PP were classified as follows:
Oral Presentations S1711) At least one 8/8 HR matched donor exists on BTMR
2) No potential 8/8 HR donors exist
3) Potential 8/8 HR donors exist
PP searches falling into category 3 (accrued untilN5 200 per race)
then had anHLA search strategy expert rank potential donors within
BTMRinorder of theirmatching likelihood.Previously storeddonor
sampleswereHRHLA tested in order of ranking and evaluated to de-
termine match status. Consecutive rounds of donor sample testing
were performed until either an 8/8 matched donor was identified or
no potential donors with stored samples remained.
Results: The table below shows the 8/8 HRmatch rate of cases to be
68% for CAU, 42% forHIS, 45% for API, and 27% for AFA. Careful
review of the cases ‘‘Pending further testing; no stored sample’’ sug-
gests that few additional cases would yield 8/8 HR matches.
CAU PP HIS PP API PP AFA PP8/8 HR Matched 258 (68%) 128 (42%) 122 (45%) 105 (27%)
Pending Further Testing;
No Stored Sample48 (13%) 65 (21%) 57 (21%) 54 (14%)No 8/8 HR Match 71 (19%) 114 (37%) 91 (34%) 231 (59%)
TOTAL 377 307 270 390Conclusions:This studyprovides a true8/8HRmatchrateestimate for
CAU,HIS, API, and AFA patients through BTMR, which has not been
accomplished previously. These results demonstrate the racial disparity
in HLA match rates and can be used to inform patients searching
BTMR.This studyalsoprovides vital information fordonor recruitment
and availability efforts. Results provide a baseline match rate that can be
further supplemented using the additional worldwide URD inventory.
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A 2 STEP APPROACH TO MYELOABLATIVE HAPLOIDENTICAL HEMATO-
POIETIC STEM CELL TRANSPLANATION (HSCT): REPORT OF A PHASE II
TRIAL WITH 18 MONTHS OF FOLLOW-UP FOR ALL PATIENTS
Grosso, D.1, Carabasi, M.1, Colombe, B.2, Cornett Farley, P.3,
Flomenberg, P.4, Filicko-O’Hara, J.1, Kasner, M.1, O’Hara, W.5,
Wagner, J.L.1, Weiss, M.1, Werner-Wasik, M.6, Flomenberg, N.1
1Thomas Jefferson Kimmel Cancer Center, Philadelphia, PA; 2Thomas Jef-
ferson University Hospital, Philadelphia, PA; 3Thomas Jefferson University
Hospital, Philadelphia, PA; 4Thomas Jefferson University Hospital, Phila-
delphia, PA; 5Thomas Jefferson University Hospital, Philadelphia, PA;
6Thomas Jefferson University Hospital, Philadelphia, PA
Haploidentical HSCT using post transplant cyclophosphamide
(CY) for elimination of alloreactive lymphocytes has been reported
as a safe option for patients lacking an HLA identical donor. We re-
port an alternate approachwith the following salient differences: mye-
loablative vs non-myeloablative conditioning, peripheral blood rather
than marrow stem cell source, no exposure vs exposure of HSC to cy-
clophosphamide, higher fixed number of CD3 cells versus a lower var-
iable number of CD3 cells in each graft. Results are reported nowwith
a followed up of 18-46 months.
Table 1. Patient Characteristics-2 Step ApproachAge 52 (19-67)AML 16Remission 7Resistant/PIF 9Biphenotypic Leukemia
(Active Disease)1ALL 4CR2 (ph-) 3Persistent Disease (PH+) 1MDS 2NHL Resistant 3SAA 1HLA MM (GVH Direction)4 133 112 20 1Patients received 12 Gy of total body irradiation (TBI), followed by
a donor lymphocyte product (DLI) containing 2  10e8 CD31
cells/kg (Step 1). This large dose of haploidentical lymphocytes re-
sulted in fever (median temperature 103.8f), diarrhea and rash. CY
60 mg/kg was given on days -3 and -2 resulting in resolution of symp-
toms. Tacrolimus and MMF were begun on day-1. A CD 34 selected
donor product was infused on day 0 (Step 2). Two of the 27 patients
died of toxicity and infection before day 14. Of the remaining 25 pa-
tients, 23 had complete engraftment while two with pre-existing
anti-donor HLA antibodies failed to engraft. Only 2 of 25 (8%) pa-
tients developed severe acuteGVHD, 3 of 25 (12%) developed limited
chronic GVHD, and no patient died of GVHD. Only two of 25 pa-
tients (8%) died of infection. Of 16 disease-free patients surviving 6
months from HSCT, median CD41 count at day 100 was 105 cells/
ml (range 10-403). Eight of 25 (32%) patients relapsed after HSCT.
Probability of survival (OS) at 1 and 3 years post transplant is 52%
and 48% respectively. All surviving patients are disease-free. OS at 3
years is 75% for patients transplanted inCR, but only 27% for patients
transplanted with active disease. KIR mismatching was not correlated
with relapse rates. In contrast, child tomother transplants for AMLap-
pear to be relapsing at higher rates than other combinations (66% vs
14%). In the context of CY tolerization, a dose of 2 10e8/kg T-cells
resulted inconsistent engraftment, prompt immune reconstitution, lit-
tle severe GVHD, acceptable toxicity, and encouraging overall sur-
vival, particularly in patients transplanted in CR. Using this 2-step
platform allows us to explore the use of alternate agents for the elimi-
nationof alloreactive lymphocytes, increase the lengthof time between
DLI andCY, and to employ twodonor strategies to improveoutcomes
in high risk patients.
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UNMANIPULATED HAPLOIDENTICAL STEM CELL TRANSPLANTATION
USING MYELOABLATIVE OR REDUCED-INTENSITY PRECONDITIONING
REGIMEN
Ikegame, K., Yoshihara, S., Kaida, K., Taniguchi, K., Inoue, T., Kato, R.,
Fujioka, T., Tamaki, H., Okada,M., Soma, T., Taniguchi, Y., Ogawa,H.
Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
Background: Related haploidentical donors, as cord blood, can be
alternative donor sources in stem cell transplantation (SCT). Severe
GVHD, however, has interfered the progress of haploidentical SCT
(haploSCT). To deal with this strong GVHD, T cell depletion has
usually been used in US and European countries. In order to pursue
the controllable GVL effect by T cells, we have performed unmanip-
ulated haploSCTusingmyeloablative or reduced intensity precondi-
tioning regimen accompanied with intensified GVHD prophylaxis.
In this meeting, we will summarize our experience of haploSCT
for more than ten years.
Patients: From August 1998 to September 2010, we have performed
351 cases of haploSCT (all cases were HLA 2-3 antigen mismatched
in GVH direction). Patients’ characteristics are sex: male 186, female
168, age: 16-65 years old (median 39), disease: AML/MDS 149, ALL
81, ML 67, others 54. 83% of cases underwent SCT in non-complete
remission (non-CR) state. Patients under 45 years old underwentmye-
loablative preconditioning regimen consisting of FLU/CA/CY/
TBI8Gy (haplo-full, n 5 100), and patients over 45 years old or
with comorbidities or repetitive SCT (including second to fifth
SCT) underwent reduced intensity preconditioning regimen consist-
ing of FLU/(CA)/BU/ATGor FLU/(CA)/MEL/ATG (haplo-mini, n
5 251). High dose Ara-C (CA) was optional to reduce tumor burden.
As ATG, ATG (Fresenius) 8mg/kg, or thymoglubulin (genzyme) 2-
4mg/kg were used. GVHD prophylaxis consisted of taclolimus
(TAC), methylprednisolone (mPSL) 2mg/kg/day, short term MTX,
and mycophenolate mofetil (MMF) 15mg/kg/day in haplo-full, and
TAC, mPSL 1mg/kg/day in haplo-mini, respectively. For elderly pa-
tients over 50 years old in haplo-mini, MMF was added.
Results: Hematopoietic engraftment in haploSCT was as rapid as
that in HLA-identical SCT, except ten cases of graft rejection. Acute
GVHD (grade II-IV) was observed in 30%. Overall survival in five
years is 30% in haplo-full and 40% in haplo-mini, respectively. If
limited to CR cases, overall survival reached over 60% in haplo-
mini. There is no difference in survival rate among patients’ diseases.
Discussion: Unmanipulated haploSCT is feasible and effective for
refractory diseases. ATG dose used in haplo-mini is critical, and
rather low compared with that of European cases reported so far.
